New Combo Trial

› Forums › General Melanoma Community › New Combo Trial

  • Post
    • September 27, 2014 at 4:11 pm
    JerryfromFauq
    Participant

      GSK and Pfizer combine melanoma drugs in new trial
      Will investigate effects of adding palbociclib to Mekinist
      The phase I/II trial will look at the effects of adding Pfizer's investigational drug palbociclib to treatment with GlaxoSmithKline's already-marketed MEK inhibitor Mekinist (trametinib), one of two GSK drugs for melanoma approved earlier this year.

      Palbociclib is an oral inhibitor of cyclin-dependent kinases (CDK) 4 and 6 and one of Pfizer's top pipeline prospects, having been granted breakthrough status by the FDA in April as a treatment for breast cancer.

      Trial 200344 is a dose-escalation, open-label study designed to determine the recommended combination regimen for trametinib plus palbociclib in patients with melanoma. It will also evaluate the effect of the combination on tumour biomarkers, safety and anti-cancer activity in patients with BRAFV600 wild type melanoma, including those with NRAS mutations.
      http://www.pmlive.com/pharma_news/gsk_and_pfizer_combine_melanoma_drugs_in_new_trial_520905

       

    Viewing 2 reply threads
    • Replies
        • September 27, 2014 at 11:59 pm
        BrianP
        Participant

          Thanks Jerry.  That seems like a viable option for someone who progresses after Ipi and Anti-PD1.  It definitely looks like Braf + is not a requirement.  Can't tell if you can be Braf + and be in the trial.  Will be curious when it gets listed on clinicaltrials.gov to see what prior treatments if any would exclude someone from the trial.

          Brian

          • September 27, 2014 at 11:59 pm
          BrianP
          Participant

            Thanks Jerry.  That seems like a viable option for someone who progresses after Ipi and Anti-PD1.  It definitely looks like Braf + is not a requirement.  Can't tell if you can be Braf + and be in the trial.  Will be curious when it gets listed on clinicaltrials.gov to see what prior treatments if any would exclude someone from the trial.

            Brian

            • September 27, 2014 at 11:59 pm
            BrianP
            Participant

              Thanks Jerry.  That seems like a viable option for someone who progresses after Ipi and Anti-PD1.  It definitely looks like Braf + is not a requirement.  Can't tell if you can be Braf + and be in the trial.  Will be curious when it gets listed on clinicaltrials.gov to see what prior treatments if any would exclude someone from the trial.

              Brian

          Viewing 2 reply threads
          • You must be logged in to reply to this topic.
          About the MRF Patient Forum

          The MRF Patient Forum is the oldest and largest online community of people affected by melanoma. It is designed to provide peer support and information to caregivers, patients, family and friends. There is no better place to discuss different parts of your journey with this cancer and find the friends and support resources to make that journey more bearable.

          The information on the forum is open and accessible to everyone. To add a new topic or to post a reply, you must be a registered user. Please note that you will be able to post both topics and replies anonymously even though you are logged in. All posts must abide by MRF posting policies.

          Popular Topics